Intraocular lens

From Wikipedia, the free encyclopedia

Jump to: navigation, search

An intraocular lens (IOL) is an implanted lens in the eye, usually replacing the existing crystalline lens because it has been clouded over by a cataract, or as a form of refractive surgery to change the eye's optical power. It usually consists of a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye. IOLs were traditionally made of an inflexible material (PMMA) though this largely been superseded by the use of flexible materials. Most IOLs fitted today are fixed monofocal lenses matched to distance vision. However, other types are available, such as multifocal IOLs which provide the patient with multiple-focused vision at far and reading distance, and adaptive IOLs which provide the patient with limited visual accommodation.

Insertion of an intraocular lens for the treatment of cataracts is the most commonly performed eye surgical procedure. The procedure can be done under local anesthesia with the patient awake throughout the operation. The use of a flexible IOL enables the lens to be rolled for insertion into the capsule through a very small incision, thus avoiding the need for stitches, and this procedure usually takes less than 30 minutes in the hands of an experienced ophthalmologist. The recovery period is about 2–3 weeks. After surgery, patients should avoid strenuous exercise or anything else that significantly increases blood pressure. They should also visit their ophthalmologists regularly for several months so as to monitor the implants.

IOL implantation carries several risks associated with eye surgeries, such as infection, loosening of the lens, lens rotation, inflammation, night time halos. Though IOLs enable many patients to have reduced dependence on glasses, most patients still rely on glasses for certain activities, such as reading.


[edit] History

First permanent insertion of intraocular lens 8 February 1950

Sir Harold Ridley was the first to successfully implant an intraocular lens on November 29, 1949, at St Thomas' Hospital at London. That first intraocular lens was manufactured by the Rayner company of Brighton, East Sussex, England from Perspex CQ made by ICI. It is said that idea of implanting an intraocular lens came to him after an intern asked him why he was not replacing the lens he had removed during cataract surgery. The first lenses used were made of glass, they were heavy and were prone to shatter during Nd:YAG capsulotomy. Plastic materials were used later, when Harold Ridley noticed that they were inert, after seeing pilots of World War II with pieces of shattered windshields in their eyes. The intraocular lens did not find widespread acceptance in cataract surgery until the 1970s, when further developments in lens design and surgical techniques had come about. Currently, more than a million IOLs are implanted annually in the United States.

[edit] Materials used for intraocular lenses

Polymethylmethacrylate (PMMA) was the first material to be used successfully in intraocular lenses. British ophthalmologist Sir Harold Ridley observed that Royal Air Force pilots who sustained eye injuries during World War II involving PMMA windshield material did not show any rejection or foreign body reaction. Deducing that the transparent material was inert and useful for implantation in the eye, Ridley designed and implanted the first intraocular lens in a human eye.

Advances in technology have brought about the use of silicone and acrylic, both of which are soft foldable inert materials. This allows the lens to be folded and inserted into the eye through a smaller incision. PMMA and acrylic lenses can also be used with small incisions and are a better choice in people who have a history of uveitis, have diabetic retinopathy requiring vitrectomy with replacement by silicone oil or are at high risk of retinal detachment. Acrylic is not always an ideal choice due to its added expense. New FDA-approved multifocal intraocular lens implants allow most post operative cataract patients the advantage of glass-free vision. These new multifocal lenses are not a covered expense under most insurance plans (In the United States, Medicare decided to stop covering them in May 2005) and can cost the patient upwards of $2800 per eye. Latest advances include IOLs with square-edge design, non-glare edge design and yellow dye added to the IOL.

In the United States, a new category of intraocular lenses was opened with the approval by the Food and Drug Administration in 2003 of multifocal and accommodating lenses. These come at an additional cost to the recipient beyond what Medicare will pay and each has advantages and disadvantages.

Multifocal IOLs - provide for simultaneous viewing of both distance vision and near vision. Some patients report glare and halos at night time with these lenses.

Accommodating IOLs - allow for both distance vision and midrange near vision. These IOLs are typically not as strong for closer vision as the multifocal IOLs.

To incorporate the strengths of each type of IOL, eye surgeons are increasing using a multifocal IOL in one eye to emphasize close reading vision and an accommodating IOL in the other eye for further midrange vision. This is called "mix and match." Distance vision is not compromised with this approach, while near vision is optimized.

Other IOLs include:

  • Blue Light Filtering IOLs filter the UV and high-energy blue light present in natural and artificial light, both of which can cause vision problems.
  • Toric IOLs (1998) correct astigmatic vision.

[edit] Phakic, aphakic and pseudophakic IOLs

Slit lamp photo of Pseudophakia: Posterior chamber Intraocular lens - note that Posterior capsular opacification is visible few months after implantation of Intraocular lens in eye, as seen on retroillumination
  • Phakia is the presence of the natural crystalline lens.
  • Aphakia is the absence of the natural crystalline lens, either from natural causes or because it has been removed.
  • Pseudophakia is the substitution of the natural crystalline lens with a synthetic lens. Pseudophakic IOLs are used in cataract surgery.

The root of these words comes from the Greek word phakos 'lens'.

[edit] Intraocular lenses for correcting refractive errors

Intraocular lenses have been used since 1999 for correcting larger errors in myopic (near-sighted), hyperopic (far-sighted), and astigmatic eyes. This type of IOL is also called PIOL (phakic intraocular lens), and the crystalline lens is not removed.

More commonly, aphakic IOLs (that is, not PIOLs) are implanted via Clear Lens Extraction and Replacement (CLEAR) surgery. During CLEAR, the crystalline lens is extracted and an IOL replaces it in a process that is very similar to cataract surgery: both involve lens replacement, local anesthesia, both last approximately 30 minutes, and both require making a small incision in the eye for lens insertion. People recover from CLEAR surgery 1-7 days after the operation. During this time, they should avoid strenuous exercise or anything else that significantly raises blood pressure. They should also visit their ophthalmologists regularly for several months so as to monitor the IOL implants. CLEAR has a 90% success rate (risks include wound leakage, infection, inflammation, and astigmatism). CLEAR can only be performed on patients ages 40 and older. This is to ensure that eye growth, which disrupts IOL lenses, will not occur post-surgery.

Once implanted, IOL lenses have three major benefits. First, they are an alternative to LASIK, a form of eye surgery that does not work for people with serious vision problems. Effective IOL implants also entirely eliminate the need for glasses or contact lenses post-surgery.[citation needed] Cataract will not return, as the lens has been removed. The disadvantage is that the eye's ability to change focus (accommodate) has generally been reduced or eliminated, depending on the kind of lens implanted.

Most PIOLs have not yet been approved by FDA, but many are under investigation, and some of the risks that FDA have been found so far during a three year study of the Artisan lens, produced by Ophtec USA Inc, are:[1]

Other risks include:

  • 0.03 - 0.05% eye infection risk, which in worst case can lead to blindness. This risk exists in all eye surgery procedures, and is not unique for IOLs.
  • glaucoma,
  • astigmatism,
  • remaining near or far sightedness,
  • rotation of the lens inside the eye within one or two days after surgery.

One of the causes of the risks above is that the lens can rotate inside the eye, because the PIOL is too short, or because the sulcus has a slightly oval shape (the height is slightly smaller than the width).

NuLens Ltd. is currently in patient trials with a new Accommodative Intraocular Lens (IOL) technology with the potential to provide over 10 diopters of accommodative power. With an IOL that sits on top of the collapsed capsular bag, the NuLens Accommodative IOL may be the first intraocular lens to provide real, comfortable, and lasting accommodation for near, intermediate and far distances.[2]

[edit] Phakic IOLs

Special types of Phakic IOLs (PIOLs) are available in patients requiring IOL implantation without removal of crystalline human lens, particularly useful in refractive surgery for high myopia. For this, the eye surgeon has to determine the size of the PIOL. If the lens is of incorrect length, then it can rotate inside the eye, causing astigmatism, and/or damage to the natural lens. It can also block the natural flow of fluid inside the eye, causing glaucoma. The size is usually estimated, by measuring white-to-white, and estimating the ciliary sulcus diameter. However, the surgeon can perform 3D ultrasound biomicroscopy with for example Artemis for a completely accurate measurement. 3D ultrasound is to traditional 2D ultrasound as computer assisted tomography is to x-ray. Therefore, 3D ultrasound examination is strongly recommended, since the white-to-white guesstimate does not have a strong correlation with sulcus-to-sulcus - neither for myopic, nor for hyperopic. About 1% of sulcus-to-sulcus estimates based on white-to-white are so wrong that serious complications can arise. This type of phakic lens has to be ordered from the manufacturer, requiring a number of weeks before the surgery. However, on the other hand, the routine posterior chamber IOLs (PC-IOLs) used for routine cataract surgical cases are available with the surgical suite or doctor's office, and the cataract surgery can usually be performed without delay once the patient is cleared for surgery.

[edit] Types of PIOLs

Phakic IOLS (PIOLs) can be either spheric or toric—the latter is used for astigmatic eyes. The difference is that toric PIOLs have to be inserted in a specific angle, or the astigmatism will not be fully corrected, or it can even get worse.

According to placement site in the eyes phakic IOLs can be divided to:

  • Angle supported PIOLs: those IOLs are placed in the anterior chamber. They are notorious for their negative impact on the corneal endothelial lining, which is vital for maintaining a healthy dry cornea.
  • Iris supported PIOLs: this type is gaining more and more popularity. The IOL is attached by claws to the mid peripheral iris by a technique called enclavation. It is believed to have a lesser effect on corneal endothelium.
  • Sulcus supported PIOLs: these IOLS are placed in the posterior chamber in front of the natural crystalline lens. They have special vaulting so as not to be in contact with the normal lens. The main complications with this type is their tendency to cause cataracts and/or pigment dispersion.

[edit] IOL manufacturers and materials

There are many different manufacturers of intraocular lenses.



  • AMO (Advanced Medical Optics) produces the Verisyse PIOL and the ReZoom multi-focal IOL.
  • Tekia Inc. produces the Kelman Duet lens.
  • The Vision Membrane phakic IOL is produced by Vision Membrane Technologies Inc., Apollo Optical Systems LLC, and Millennium Biomedical Inc.
  • The PRL Phakic Refractive Lens is produced by Medennium, distributed by IOLTech.


  • Staar produces the Visian ICL lens, in a material called Collamer.
  • Alcon produces the multi-focal AcrySof ReSTOR and the AcrySof Toric IOLs.
  • Eyeonics produces the Accommodating Crystalens IOL.

[edit] See also

[edit] Notes

  1. ^ Staff (September 13, 2004). "FDA Approves Implanted Lens to Correct Nearsightedness (T03-38)". FDA Talk Paper. Food and Drug Administration. Retrieved on May 21 2006. 
  2. ^ Dambaugh, Gabe (2008-06-06), "Medical Applications" (PDF), NEi Nastran FEA Case Study: 1, 

[edit] References

[edit] External links

Personal tools